VOLITIONRX LTD (VNRX)

VOLITIONRX is a molecular diagnostics company focused on developing and commercializing blood-based tests for cancer detection and monitoring. The company uses proprietary technology to analyze proteins in blood samples, aiming to identify cancer at early stages or track disease progression in patients already diagnosed. Like all diagnostic companies, VOLITIONRX’s economics depend on test volume, the price it can charge per test, and the cost of delivering those tests — a model fundamentally different from pharmaceutical companies or medical-device manufacturers, even though all three operate in the healthcare space.

What exactly is VOLITIONRX trying to do?

VOLITIONRX is developing proprietary blood tests — referred to as liquid biopsies — that can detect cancer by measuring specific proteins or DNA fragments present in blood samples. The core idea is that cancerous tumours shed identifiable molecular markers into the bloodstream, and by measuring those markers with sufficient sensitivity and specificity, a test can identify cancer earlier than conventional imaging or tissue biopsy, or can monitor whether a patient’s cancer is responding to treatment. If successfully developed and commercialized, such tests could be used by physicians as screening tools (to identify cancer in asymptomatic people) or as monitoring tools (to track disease burden in patients already in treatment).

The company’s primary technology platform focuses on protein analysis. Blood contains thousands of proteins, and cancer cells produce or alter proteins in ways that differ from healthy cells. VOLITIONRX has developed assays — laboratory tests — that measure specific proteins believed to be cancer-associated, and it uses those measurements to generate a diagnostic signal. The company has spent years validating these tests through clinical studies, trying to achieve levels of sensitivity (ability to detect cancer when it is present) and specificity (ability to correctly identify healthy people as healthy) that are high enough to be clinically useful and commercially viable.

Why is this such a difficult business?

Diagnostic companies face a unique combination of regulatory, clinical, and commercial hurdles. First, regulatory: any diagnostic test sold commercially in the United States must either meet the criteria for an FDA-approved laboratory-developed test or meet criteria for Clinical Laboratory Improvement Amendments (CLIA) certification. These approval pathways require extensive clinical validation showing that the test works — that is, it reliably detects the disease it claims to detect and does not generate excessive false positives. That validation requires collecting blood samples from hundreds or thousands of patients, running the test on those samples, and correlating results with actual disease outcomes. Validation studies take years and cost millions of dollars.

Second, clinical: even if a test meets regulatory requirements, it must demonstrate clinical utility — meaning that acting on its results actually improves patient outcomes. A test that detects a cancer that would have been caught anyway by screening with conventional imaging may be technically accurate but clinically superfluous. Conversely, a test that identifies cancers too early (before symptoms develop and before treatment would change prognosis) may raise patient anxiety without improving health. The evidence bar for clinical utility is high and requires large prospective studies.

Third, commercial: once a test is validated and approved, a company must actually persuade physicians to order it and must build a business model that generates revenue. For a screening test, that means building awareness among primary-care physicians and patients, often through direct-to-consumer marketing — an expensive channel. For a monitoring test, that means establishing relationships with oncologists. Revenue per test is typically in the hundreds of dollars, comparable to other molecular diagnostic tests, but volume-dependent. VOLITIONRX must process thousands of samples per month to achieve meaningful scale.

How does VOLITIONRX actually make money?

The company generates revenue by running tests. When a physician orders a test, a patient submits a blood sample, VOLITIONRX processes it in its laboratory (or through a clinical laboratory partner), and the company bills for the test — either to the patient’s insurance, to Medicare or Medicaid, or to the patient directly. Revenue depends on the number of tests performed and the average price per test. Cost of goods sold includes sample processing, reagents, and labour — the direct cost of running the test. The difference between revenue per test and the cost per test is the gross profit, and that margin must cover all of the company’s fixed costs: facility overhead, salaries for non-laboratory staff, research and development, sales and marketing, and general administration.

For a diagnostic company, the unit economics hinge on volume. A test that costs $50 to run and sells for $300 generates $250 gross profit — an 83% gross margin — but only if the company achieves consistent volume. If the company runs only a few hundred tests per month, that $250 margin per test will not cover the fixed costs of maintaining a laboratory and a sales team. Scale is essential. VOLITIONRX must therefore drive adoption: convince more physicians to order tests, expand into new oncology indications, and ideally achieve such clinical traction that tests become standard of care.

What are the real risks VOLITIONRX faces?

Competition is substantial. Established diagnostics companies (companies with large existing test menus and established physician relationships), as well as newly founded liquid-biopsy startups, are all developing blood tests for cancer. Some are backed by large pharmaceutical companies or major healthcare systems that provide distribution advantages. VOLITIONRX must compete on the basis of clinical performance, convenience, turnaround time, and physician familiarity — a challenging position for a smaller company.

Regulatory changes are always a risk. If regulatory bodies tighten the standards for approving new diagnostic tests, or if payers (insurance companies and Medicare) become less willing to reimburse specific tests, commercial viability suffers immediately. Conversely, if regulators require clinical evidence that is more stringent than VOLITIONRX has generated, tests could be delayed or rejected.

A third risk is that the company’s tests, once approved, may not achieve the clinical adoption rate management projects. Physicians are accustomed to existing screening and diagnostic pathways and switch away only if the new test is clearly superior or more convenient. If adoption is slower than expected, revenue per patient or per physician falls, margins are pressured, and the company may burn cash faster than projected.

How to research VOLITIONRX as an investment

Start with VOLITIONRX’s 10-K and quarterly filings (SEC CIK 0000093314), which disclose revenue, the number of tests processed, average revenue per test, and cost of goods sold. The company should be transparent about which tests are in development, how many are already commercialized, and what regulatory approvals are pending. Look for signs of revenue growth, expanding test volume, and improving gross margins as scale increases. Watch the balance sheet for cash and cash burn — how long the current cash runway is — because diagnostics companies often operate at a loss during the validation and early commercialization phase. Listen to earnings calls for updates on clinical validation studies, new test launches, and adoption trends with key customer groups. Monitor clinical-conference presentations and peer-reviewed publications where the company presents validation data; clinical credibility is essential for driving physician adoption. Track reimbursement decisions from major payers, as payer coverage directly drives volume and revenue potential.